Dr. Patel is an expert in the treatment of myeloproliferative neoplasms, myelodysplastic syndromes, and leukemia. He is an active researcher whose work is focused on the development of clinical trials to investigate novel therapies that may improve the standard of care for patients with myeloid cancers and leukemia. Dr. Patel has published his research in several well-respected peer-reviewed journals including Blood, Blood Advances, the British Journal of Haematology, Cancer, JCI Insight, and Bone Marrow Transplantation.
University of Chicago
Chicago, IL
Fellowship - Hematology-Oncology
2021
McGaw Medical Center of Northwestern University
Chicago, IL
Chief Residency - Internal Medicine
2018
McGaw Medical Center of Northwestern University
Chicago, IL
Residency - Internal Medicine
2017
University of Missouri School of Medicine
Columbia, MO
MD - Medicine
2014
Northwestern University
Evanston, IL
BA - Economics
2010
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials.
Impact of Modernizing Eligibility Criteria on Enrollment and Representation in Acute Myeloid Leukemia Clinical Trials. Blood. 2025 Oct 16.
PMID: 41100728
Outcomes of older patients with TP53-mutated myeloid neoplasms.
Outcomes of older patients with TP53-mutated myeloid neoplasms. Blood Cancer J. 2025 Oct 07; 15(1):160.
PMID: 41057316
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis.
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis. Blood Cancer J. 2025 Oct 06; 15(1):158.
PMID: 41053057
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
PMID: 40813576
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Haematologica. 2025 Jul 24.
PMID: 40702896
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review.
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2025 Jul 03.
PMID: 40668166
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
PMID: 40521395
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Adv. 2025 May 27; 9(10):2453-2457.
PMID: 39969200
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status.
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status. Br J Haematol. 2025 May 22.
PMID: 40400334
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Mar 14.
PMID: 40085959